NCT03051074 is a NA clinical trial of Floating in Generalized Anxiety Disorder, sponsored by Laureate Institute for Brain Research, Inc..

Who is sponsoring NCT03051074?

NCT03051074 is sponsored by Laureate Institute for Brain Research, Inc..

What drugs are being tested in NCT03051074?

Interventions in NCT03051074: Floating, Comparison.

What condition does NCT03051074 study?

NCT03051074 studies Generalized Anxiety Disorder, Agoraphobia, Panic Disorder, PostTraumatic Stress Disorder, Social Anxiety Disorder, Major Depressive Disorder.

Is NCT03051074 still recruiting?

NCT03051074 is currently completed. Last updated 6 October 2023.

Last reviewed 2023-10-06 · How we verify

NCT03051074

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Examining the Effects of Reduced Environmental Stimulation on Anxiety

Completed NA Last updated 6 October 2023

What this trial tests

NA trial testing Floating in Generalized Anxiety Disorder in 60 participants. Completed in 31 December 2019.

Timeline

1 December 2016

Primary endpoint
1 December 2019

31 December 2019

Quick facts

Lead sponsor	Laureate Institute for Brain Research, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	basic science
Enrollment	60
Start date	1 December 2016
Primary completion	1 December 2019
Estimated completion	31 December 2019
Sites	1 location across United States

Drugs / interventions tested

Floating
Comparison

Conditions studied

Generalized Anxiety Disorder — all drugs for Generalized Anxiety Disorder →
Agoraphobia — all drugs for Agoraphobia →
Panic Disorder — all drugs for Panic Disorder →
PostTraumatic Stress Disorder — all drugs for PostTraumatic Stress Disorder →

Sponsor

Laureate Institute for Brain Research, Inc.

Who can join

Adults 18 to 55, any sex, with Generalized Anxiety Disorder or Agoraphobia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The studies proposed in this protocol aim to explore the anxiolytic properties of floating as it relates to the central and autonomic nervous system.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The Elicitation of Relaxation and Interoceptive Awareness Using Floatation Therapy in Individuals With High Anxiety Sensitivity.
Feinstein JS, Khalsa SS, Yeh H, Al Zoubi O, et al · · 2018 · cited 50× · PMID 29656950 · DOI 10.1016/j.bpsc.2018.02.005
Examining the short-term anxiolytic and antidepressant effect of Floatation-REST.
Feinstein JS, Khalsa SS, Yeh HW, Wohlrab C, et al · · 2018 · cited 45× · PMID 29394251 · DOI 10.1371/journal.pone.0190292
Exploring the acute cardiovascular effects of Floatation-REST.
Flux MC, Fine TH, Poplin T, Al Zoubi O, et al · · 2022 · cited 14× · PMID 36570829 · DOI 10.3389/fnins.2022.995594

Verify or expand the search:

Other trials of Floating

Trials testing the same drug.

NCT03584750 — Floating for Chronic Pain · NA · completed
NCT02452203 — Examining the Effects of Reduced Environmental Stimulation on the Brain · NA · completed

Other recruiting trials for Generalized Anxiety Disorder

Currently open trials in the same condition.

NCT06661460 — Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders · NA · recruiting
NCT06934525 — Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings · NA · recruiting
NCT07305701 — Cohort Study on Medical Students' Mental Health · recruiting
NCT07330648 — Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder · Phase 2 · recruiting
NCT07121712 — Navigated cTBS for the Treatment of Generalized Anxiety Disorder · NA · recruiting

Other Laureate Institute for Brain Research, Inc. trials

Trials by the same sponsor.

NCT06410196 — Mood and Decision-making in Methamphetamine Use Disorder · NA · recruiting
NCT06088732 — Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression · Phase 1, PHASE2 · recruiting
NCT06219681 — Modulating Repetitive Negative Thinking Related Brain Networks in Young Adults With Depression · NA · terminated
NCT06004115 — Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression · Phase 4 · recruiting
NCT06486584 — Contingency Management for Problematic Behavior Reduction in the Community · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03051074 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Laureate Institute for Brain Research, Inc.
Last refreshed: 6 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03051074.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing